明基医院通过港交所聆讯 为华东地区最大的民营营利性综合医院集团

Core Viewpoint - Ming Chi Hospital Group is preparing for an IPO on the Hong Kong Stock Exchange, with CICC and Citibank as joint sponsors [1]. Company Overview - Ming Chi Hospital is a private for-profit hospital group in mainland China, operating two hospitals: Nanjing Ming Chi Hospital and Suzhou Ming Chi Hospital [3]. - The company is the largest private for-profit hospital group in East China by total revenue in 2024, holding a market share of 1.0% in the region and ranking seventh nationally with a market share of 0.4% [3]. - The company ranks first among all private for-profit hospital groups in mainland China in terms of revenue per bed for 2024 [3]. Hospital Operations - As of June 30, 2025, the two hospitals have a combined area of approximately 400,000 square meters and a total of 1,850 registered beds, supported by a team of over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [3]. - In 2024, the hospitals are expected to serve over 2 million outpatient visits and perform more than 22,000 inpatient surgeries [3]. Nanjing Ming Chi Hospital - Nanjing Ming Chi Hospital began operations in 2008 and was rated as a Class III Grade A hospital in 2022, being the first private hospital in Nanjing to achieve this rating [4]. - It is the third-largest private for-profit hospital in China by total revenue in 2024, with a market share of 0.3% nationally and 2.0% in Jiangsu Province [4]. - The hospital has received multiple national certifications, including being a certified chest pain center and a national health management demonstration base [4]. Suzhou Ming Chi Hospital - Suzhou Ming Chi Hospital started operations in 2013 and is a Class III comprehensive hospital [4]. - It received JCI accreditation in 2020 and is recognized as a national chest pain center and a stroke prevention center [4]. - The hospital has developed unique advantages in departments such as obstetrics and pediatrics, and has been recognized as a "Jiangsu Province Elderly-Friendly Medical Institution" [4]. Financial Performance - The company reported revenues of approximately RMB 2.336 billion, RMB 2.688 billion, and RMB 2.659 billion for the years 2022, 2023, and 2024, respectively [5]. - The profit for the same periods was approximately RMB 89.55 million, RMB 167.45 million, and RMB 108.92 million [5]. - For the six months ending June 30, 2024, and 2025, the revenues were approximately RMB 1.330 billion and RMB 1.312 billion, with profits of RMB 63.40 million and RMB 48.70 million, respectively [5].